Pregnancy outcomes in women with imported malaria in mainland France: A retrospective study from 2004 to 2014

Objectives: There is little data on pregnant women with imported malaria in high-income countries, especially regarding offspring outcomes. We wanted to determine pregnancy outcomes of imported malaria in pregnant women in mainland France. Patients and methods: We conducted a retrospective, descriptive study of outcomes in pregnant women hospitalized with malaria from 2004 to 2014 in two regions of mainland France. An adverse outcome was defined as a miscarriage, stillbirth, preterm birth (<35 weeks of gestation), low birth weight (LBW) defined as less than 2500 g, or congenital malaria. Results: Of 60 pregnancies, 5 were excluded because of elective abortions; 55 were investigated, of which 11 were primigravidae and 44 multigravidae. Pregnancies were singleton (n = 51) or twin (n = 4). Mean age was 30.4 years (range:19–45 y). Among the 55 cases, 9 ended in a miscarriage (8 singletons and 1 twin pregnancy) and 1 had a stillbirth at 21 weeks of gestation, all immediately after the malarial episode. 45 gave birth (29 vaginal deliveries and 16 caesarean sections) to 48 (42 singletons and 6 twins) newborns. Amongst these, 30 were healthy full-term newborns, 10 had LBW, and 8 were preterm. Overall, 26 of 55 (47.3%) pregnancies, and 29 of 59 (49.2%) offsprings had adverse outcomes. Compared to singleton pregnancies, twin pregnancies were associated with adverse outcomes (p = 0.0438). Conclusions: Imported malaria has a severe impact on pregnancy outcomes. Prevention and management of imported malaria in pregnancy should be optimized

Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: Preliminary results of the feasibility EPIONE trial

Contexte et objectif: La préservation de la qualité de vie après un traitement anticancéreux est un défi majeur pour les survivantes du cancer du sein. Environ 42 à 70 % des patients qui reçoivent une thérapie systémique pour le cancer du sein, y compris une thérapie endocrinienne, développeront une atrophie vulvo-vaginale (AVV). Pour ces patientes, les traitements à base de gel couramment proposés pour les applications topiques sont restrictifs. Récemment, des approches thérapeutiques innovantes et non hormonales, telles que la thérapie laser, ont fait leur apparition. L'objectif de cette étude de faisabilité est d’étudier la sécurité et l'efficacité de la thérapie au laser CO2 chez les femmes ayant des antécédents de cancer du sein. Matériel et méthodes: Cette étude monocentrique prospective a porté sur 20 patientes atteintes d'AVV qui ont été traitées à l'hôpital universitaire Henri Mondor entre 2017 et 2018. Nous avons inclus des patientes ayant un indice de santé vaginale (IHV) 11, et à M6, seuls 15 % avaient un score de détresse sexuelle féminine > 11. Aucun effet secondaire n'a été signalé lors du suivi. Conclusion: Cette étude de faisabilité pilote a montré que le traitement par laser au dioxyde de carbone semble être une méthode efficace et sûre pour améliorer la trophicité et diminuer la sécheresse de la muqueuse vaginale chez les femmes atteintes d'atrophie vulvo-vaginale qui s'est développée après un traitement systémique du cancer du sein

Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: Preliminary results of the feasibility EPIONE trial

International audienceBackground and objective: Quality of life preservation after anti-cancer therapy is a major challenge for breast cancer survivors. Approximately 42-70% of patients who receive systemic therapy for breast cancer, including endocrine therapy, will develop vulvovaginal atrophy (VVA). For these patients, the commonly proposed gel-based treatments for topical applications are restrictive. Recently, innovative, non-hormonal therapeutic approaches, such as laser therapy, have emerged. The purpose of this feasibility study is to investigate the safety and efficacy of CO2 laser therapy in women with a history of breast cancer.Material and methods: This prospective monocentric study included 20 patients with vulvovaginal atrophy who were treated at Henri Mondor University Hospital between 2017 and 2018. We included patients with a vaginal health index (VHI) score11, and at M6, only 15% had a female sexual distress score>11. No side effects were reported during follow-up.Conclusion: This pilot feasibility study showed that carbon dioxide laser treatment appears to be an effective and safe method to improve the trophicity and decrease vaginal mucosal dryness in women with vulvovaginal atrophy that developed after systemic breast cancer therapy

Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: A phase 2 pilot study

Objective: Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer. Methods: We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of 15 showed a successful treatment outcome. The FSD score decreased significantly during the study, from a baseline score of 36.35-2.53 pretreatment to 30.15-2.47 6 months after treatment, representing improvement of 17% (P<0.0001, respectively). No adverse events were reported. Conclusions: The injection of A-PRP-HA appeared to be a promising method to improve the trophicity and hydration of vaginal mucosa for the treatment of VVA in postmenopausal breast cancer survivors with contraindications to hormone therapy